{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARWR",
    "last_updated": "2026-02-05"
  },
  "name": "Arrowhead Pharmaceuticals",
  "ticker": "ARWR",
  "has_data": true,
  "company": {
    "name": "Arrowhead Pharmaceuticals",
    "ticker": "ARWR"
  },
  "classification": {
    "stage": "Platform/Clinical",
    "modality": "RNA Therapeutics (RNAi)",
    "therapeutic_focus": ["Cardiovascular", "Metabolic", "Pulmonary", "Rare Disease"],
    "market_cap": "$8.6B",
    "exchange": "NASDAQ"
  },
  "core_thesis": "Arrowhead's TRiM platform enables extra-hepatic RNAi delivery, differentiating from Alnylam's liver-focused approach. Near-term catalysts in obesity (ARO-INHBE) and approved Plozasiran provide multiple shots on goal.",
  "one_liner": "RNAi platform company with extra-hepatic (lung, muscle, adipose) delivery capability via TRiM technology",
  "investment_thesis": {
    "bull_case": [
      "TRiM platform enables delivery to lung, muscle, and adipose tissue â€” not just liver",
      "Plozasiran (REDEMPLO) approved Nov 2025 - first RNAi therapeutic for APOC3 with 80% TG reduction",
      "ARO-INHBE targets INHBE gene, a validated obesity pathway; Phase 1 data showed 6-9% weight loss",
      "Zodasiran Phase 3 recruiting in HoFH with 65% LDL-C reduction",
      "Amgen and Takeda partnerships validate platform and provide commercial infrastructure",
      "Deep pipeline provides multiple shots on goal"
    ],
    "bear_case": [
      "Alnylam dominates RNAi space with established commercial infrastructure",
      "ARO-INHBE obesity data still early; 6-9% may not be competitive with GLP-1s (15-25%)",
      "Partner concentration - Amgen and Takeda control key assets",
      "sHTG competition from Ionis olezarsen (Tryngolza)",
      "Execution risk on extra-hepatic delivery claims"
    ]
  },
  "assets": [
    {
      "file": "plozasiran.json",
      "name": "Plozasiran",
      "alternate_names": ["ARO-APOC3", "REDEMPLO"],
      "target": "APOC3",
      "stage": "Approved (FCS) / Phase 3 (sHTG)",
      "modality": "siRNA",
      "partner": "Amgen",
      "one_liner": "First RNAi for APOC3 with 80% TG reduction - approved Nov 2025"
    },
    {
      "file": "zodasiran.json",
      "name": "Zodasiran",
      "alternate_names": ["ARO-ANG3"],
      "target": "ANGPTL3",
      "stage": "Phase 2/3",
      "modality": "siRNA",
      "partner": "Amgen",
      "one_liner": "Dual LDL-C (65%) and TG (70%) reduction with quarterly dosing"
    },
    {
      "file": "fazirsiran.json",
      "name": "Fazirsiran",
      "alternate_names": ["ARO-AAT"],
      "target": "AAT",
      "stage": "Phase 3",
      "modality": "siRNA",
      "partner": "Takeda",
      "one_liner": "96% Z-AAT reduction for AATD liver disease"
    },
    {
      "file": "aro-inhbe.json",
      "name": "ARO-INHBE",
      "target": "INHBE",
      "stage": "Phase 1/2",
      "modality": "siRNA",
      "partner": "Wholly-owned",
      "one_liner": "Novel obesity approach with 6-9% weight loss, quarterly dosing, no GI AEs"
    },
    {
      "file": "aro-alk7.json",
      "name": "ARO-ALK7",
      "target": "ALK7",
      "stage": "Phase 1/2",
      "modality": "siRNA",
      "partner": "Wholly-owned",
      "one_liner": "Receptor-targeting approach to activin E obesity pathway"
    }
  ],
  "catalysts": [
    {
      "event": "Plozasiran sHTG PDUFA decision",
      "timing": "H1 2026",
      "asset": "Plozasiran",
      "importance": "critical"
    },
    {
      "event": "SHASTA-3/4 Phase 3 sHTG data",
      "timing": "2026",
      "asset": "Plozasiran",
      "importance": "high"
    },
    {
      "event": "Zodasiran Phase 3 HoFH data",
      "timing": "2026-2027",
      "asset": "Zodasiran",
      "importance": "high"
    },
    {
      "event": "ARO-INHBE Phase 1/2 dose-expansion data",
      "timing": "2026",
      "asset": "ARO-INHBE",
      "importance": "high"
    },
    {
      "event": "SEQUOIA Phase 3 data",
      "timing": "2028",
      "asset": "Fazirsiran",
      "importance": "medium"
    }
  ],
  "partnerships": [
    {
      "partner": "Amgen",
      "assets": ["Plozasiran", "Zodasiran"],
      "type": "Development/Commercial",
      "upfront": "$35M",
      "milestones": "$617M",
      "received": "$120M",
      "royalties": "Tiered, low double-digit"
    },
    {
      "partner": "Takeda",
      "assets": ["Fazirsiran"],
      "type": "Development/Commercial",
      "upfront": "$300M",
      "milestones": "$1,040M",
      "received": "$340M",
      "royalties": "Tiered on net sales"
    },
    {
      "partner": "Johnson & Johnson (Janssen)",
      "assets": ["JNJ-3989", "JNJ-75220795"],
      "type": "Development/Commercial",
      "upfront": "$250M",
      "milestones": "$1,600M",
      "received": "$375M",
      "royalties": "Mid-single to low-double digit"
    }
  ],
  "pipeline_summary": {
    "approved": 1,
    "phase_3": 3,
    "phase_1_2": 4,
    "total_programs": 15,
    "key_modality": "RNAi (TRiM platform)"
  },
  "platform": {
    "name": "TRiM (Targeted RNAi Molecule)",
    "description": "Proprietary ligand-targeting chemistry enabling tissue-specific delivery of siRNA therapeutics",
    "tissue_targets": [
      {"tissue": "Liver (GalNAc)", "status": "Most advanced, multiple programs"},
      {"tissue": "Lung (inhaled)", "status": "ARO-RAGE, ARO-MUC5AC"},
      {"tissue": "Muscle", "status": "ARO-DUX4 (FSHD), ARO-DM1"},
      {"tissue": "CNS", "status": "ARO-MAPT (Alzheimer's), ARO-ATXN2"}
    ],
    "competitive_advantages": [
      "Extra-hepatic delivery capability differentiates from Alnylam",
      "Quarterly dosing with deep, durable knockdown",
      "Multiple tissue targeting from single platform"
    ]
  }
}
